Latest News & Features
Americas
Many players are piling into the scrum surrounding the patent eligibility of CRISPR technology. Mercedes Meyer of Drinker Biddle & Reath discusses the legal implications of CRISPR as a potential groundbreaking foundation technology. 17 September 2015
Asia
The Indian Pharmaceutical Alliance has dropped its opposition to a patent application filed by Gilead Sciences covering its hepatitis C drug Sovaldi. 16 September 2015
Americas
A US appeals court has revived a dispute in which a lower court previously ruled that there should not be a trial to determine whether pharmaceutical company Hospira infringed three patents. 14 September 2015
Big Pharma
The English High Court has ruled that Pfizer’s second medical use patent covering its drug Lyrica (pregabalin) is invalid and that the pharmaceutical company is liable for making “groundless threats” of infringement. 11 September 2015
Biotechnology
Supplementary protection certificates should take effect once an applicant for marketing authorisation has been notified of the authorisation, an advocate-general has urged the Court of Justice of the European Union to confirm. 10 September 2015
Big Pharma
Aldgate Tower will make an ideal home for the UK division of the UPC, with many advantages for its likely users, says Claire Phipps-Jones of Bristows. 10 September 2015
Biotechnology
An adviser at Europe’s highest court is expected to issue an opinion on whether the term of a supplementary protection certificate begins once it is authorised or when the applicant has been notified about it. 9 September 2015
Asia
Pfizer has had a patent application for tofacitinib, which is marketed as Xeljanz and Jakvinus, rejected by the Indian Patent Office for the second time. 8 September 2015
Americas
Biopharmaceutical company Omeros has hit its competitor Par Pharmaceutical with two lawsuits at US district courts over the drug company’s attempt to market a generic version of its Omidria product. 7 September 2015
Americas
Drug maker Sandoz has officially launched its Zarxio biosimilar after a US appeals court declined to issue an injunction that would have prevented it from being sold. 4 September 2015